ASBP Aspire-Lakewood Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1847345 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY41.6%
TTM EPS YoY201.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-25.0%
Operating margin-7,494.8%
Net margin-11,314.1%
FCF margin—
EBITDA margin—
Returns
ROE-1,032.1%
ROA-152.1%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.2%
Debt / equity0.00x
Current ratio7.99x
Interest coverage-0.79x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-53.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $63,104 | $28,353 | $4,261 | $1,941 | — | — | — | — |
| Cost of revenue | $50,818 | $22,603 | $5,261 | $1,057 | — | — | — | — |
| Gross profit | -$30,086 | $5,750 | -$1,000 | $884 | — | — | — | — |
| R&D expense | $233,482 | $296,723 | $100,035 | $207,899 | $352,887 | $263,093 | $116,356 | $7,000 |
| SG&A expense | $970,211 | $1.02M | $1.66M | $512,993 | $395,692 | $15.07M | $529,616 | $191,578 |
| Operating income | -$2.68M | -$1.65M | -$1.85M | -$1.15M | -$799,890 | -$15.56M | -$667,722 | -$215,256 |
| Interest expense | $0 | $1.60M | $6.23M | $1.48M | $527,893 | $289,931 | — | — |
| Pretax income | -$1.27M | -$3.22M | — | — | -$1.98M | -$15.94M | — | — |
| Income tax | — | — | — | — | — | — | $0 | $1,013 |
| Net income | -$1.27M | -$3.22M | -$4.71M | -$1.85M | -$1.98M | -$15.94M | -$765,710 | -$216,269 |
| EPS (basic) | -1.22 | -20.57 | — | -0.04 | -48.19 | -504.88 | — | -0.01 |
| EPS (diluted) | -1.22 | -20.57 | — | -0.04 | -48.19 | -504.88 | — | -0.01 |
| Weighted avg. shares (diluted) | 1.04M | 156,685 | — | 49.53M | 41,111 | 31,575 | — | 27.60M |
| Balance sheet | ||||||||
| Cash & equivalents | $12.17M | $5.86M | $1.00M | $1.95M | $206,233 | $1.35M | $3,633 | $16,541 |
| Inventory | $288,450 | $369,974 | $253,160 | $35,437 | — | — | — | — |
| Current assets | $13.47M | $7.12M | $1.31M | $2.40M | $989,422 | $1.97M | $147,989 | $61,809 |
| Total assets | $13.54M | $7.12M | $1.31M | $2.40M | $989,422 | $1.97M | $147,989 | $6.66M |
| Current liabilities | $1.69M | $3.15M | $7.59M | $13.86M | $10.56M | $9.87M | $1.69M | $6.57M |
| Total liabilities | $1.78M | $3.25M | $7.69M | $13.87M | $10.61M | $9.92M | $1.69M | $6.57M |
| Shareholders' equity | $11.76M | $3.87M | -$6.38M | -$11.47M | -$9.62M | -$7.95M | -$1.54M | -$774,378 |
| Shares outstanding | 1.30M | 167,470 | 117,780 | 49.53M | 49.53M | 48.90M | 690,044 | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.12M | -$3.04M | -$927,841 | -$1.10M | -$1.14M | -$1.75M | $479,569 | -$495,540 |
| Investing cash flow | — | — | — | — | — | — | $0 | $0 |
| Financing cash flow | $8.43M | $7.89M | -$16,526 | $2.85M | $0 | $3.09M | -$492,477 | $492,477 |
| Stock-based compensation | $157,500 | $13,406 | $0 | $0 | $0 | $14.13M | $0 | $0 |
| Share buybacks | — | — | — | — | — | — | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 20 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.